Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

BET inhibitor therapy did not reduce MACE in high risk, well-treated patients with T2DM

News - Nov. 17, 2019

AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patients with recent ACS and low HDL-c.

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia
Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

SGLT2i gives consistent CV benefit in HFrEF patients with or without T2DM

News - Nov. 16, 2019

AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.

Decrease in eGFR associated with future risk of renal and CV events in patients with T2DM

Literature - Nov. 4, 2019 - Oshima M et al., - Diabetologia 2019

A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.

SGLT2 inhibition reduces risk for kidney outcomes in T2DM patients

Literature - Oct. 24, 2019 - Neuen BL, et al. - Lancet Diabetes Endocrinol. 2019

A systematic review and meta-analysis of four trials shows that SGLT2 inhibition reduces the risk for dialysis, kidney transplantation, or death due to kidney disease in T2DM patients.

SGLT2i approved for treatment of DKD and reduction of HHF in T2DM patients with DKD

News - Oct. 23, 2019

Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.

FDA approves SGLT2i for reduction of HF hospitalization in T2DM with high CV risk

News - Oct. 22, 2019

Dapagliflozin is now approved by the FDA to reduce the risk of hospitalization for HF in T2DM patients with high CV risk.

Subgroup analyses in GLP1-RA trial meta-analysis to understand the varying outcomes seen with different GLP-1RAs

Literature - Oct. 22, 2019 - Kristensen SL et al., - Lancet Diabetes Endocrinol. 2019

A meta-analysis of GLP-1RA outcome trials show that treatment reduces the risk of CV and kidney events in T2DM. Subgroup analyses did not explain previously observed differences in trial results.

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.

Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.

Remission of T2DM achieved in general population without extreme lifestyle intervention

Literature - Oct. 16, 2019 - Dambha-Miller H et al., - Diabet Med. 2019

In the ADDITION-Cambridge population-based study, 30% of participants achieved remission of T2DM after 5 years, mostly those who lost ≥10% body weight early in the T2DM disease trajectory.

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD
Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.

CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.